Mydecine Innovations Group Company Description

Mydecine Innovations Group Inc., a biotechnology company, engages in the research, development, and commercialization of psilocybin products to treat mental health conditions.

The company primarily focuses on treating nicotine addiction and post-traumatic stress disorder. It also develops MYCO-005, MYCO-006, and MYCO-007 for MDMA and psilocybin analogs.

The company has a partnership with Applied Pharmaceutical Innovation for pharmaceutical drug discovery, research, and development on empathogenic and entactogenic compounds.

Mydecine Innovations Group Inc. was formerly known as NewLeaf Brands Inc. and changed its name to Mydecine Innovations Group Inc. in June 2020.

The company was incorporated in 2013 and is headquartered in Vancouver, Canada.

Mydecine Innovations Group Inc.

Country	Canada
Founded	2013
Industry	Drug Manufacturers - Specialty & Generic
Sector	Healthcare
CEO	David Bartch

Contact Details

Address: 1075 West Georgia Street Vancouver, British Columbia V6E 3C9 Canada
Phone	604 687 2038
Website	mydecine.com

Stock Details

Ticker Symbol	MYCO
Exchange	Canadian Securities Exchange
Fiscal Year	January - December
Reporting Currency	CAD
SIC Code	0100

Key Executives

Name	Position
William Cook	Interim Chief Executive Officer and Technical Director of Mindleap Health Inc.
David Joshua Bartch	Co-Founder, Chief Executive Officer, President and Chairman of the Board
Robert Roscow M.A.	Co-Founder and Former Chief Scientific Officer
Damon Michaels	Co-Founder
John Charles Ross CA, CPA, M.B.A.	Chief Financial Officer and Corporate Secretary
Dr. Rakesh Jetly FRCPC, M.D.	Chief Medical Officer
Morgan Kervitsky	Director of Marketing
Michel Rudolphie	President of the European Operations